Intrahepatic cholangiocarcinoma with arterial phase hyperenhancement and specialized tumor microenvironment associated with good prognosis after radical resection: A single-center retrospective study.

[1]  R. Higuchi,et al.  Adjuvant S-1 compared with observation in resected biliary tract cancer (JCOG1202, ASCOT): a multicentre, open-label, randomised, controlled, phase 3 trial , 2023, The Lancet.

[2]  Jiayun Guo,et al.  Cuproptosis-Related Signature Predicts the Prognosis, Tumor Microenvironment, and Drug Sensitivity of Hepatocellular Carcinoma , 2022, Journal of immunology research.

[3]  Linping Xu,et al.  Identification of macrophage correlated biomarkers to predict the prognosis in patients with intrahepatic cholangiocarcinoma , 2022, Frontiers in Oncology.

[4]  Hassam Ali,et al.  Changing incidence and survival of intrahepatic cholangiocarcinoma based on Surveillance, Epidemiology, and End Results Database (2000-2017) , 2022, Annals of hepato-biliary-pancreatic surgery.

[5]  Minqi Zhu,et al.  Tumor microenvironment characterization in esophageal cancer identifies prognostic relevant immune cell subtypes and gene signatures , 2021, Aging.

[6]  J. Ferlay,et al.  Global, regional and national burden of primary liver cancer by subtype. , 2021, European journal of cancer.

[7]  Bradford J. Kim,et al.  Arterial enhancement pattern predicts survival in patients with resectable and unresectable intrahepatic cholangiocarcinoma. , 2021, Surgical oncology.

[8]  K. Sugimachi,et al.  Cancer-associated fibroblast senescence and its relation with tumour-infiltrating lymphocytes and PD-L1 expressions in intrahepatic cholangiocarcinoma , 2021, British Journal of Cancer.

[9]  M. Kudo,et al.  Impact of hepatitis C virus on survival in patients undergoing resection of intrahepatic cholangiocarcinoma: Report of a Japanese nationwide survey , 2021, Hepatology research : the official journal of the Japan Society of Hepatology.

[10]  G. Brandi,et al.  PD-L1, TMB, MSI, and Other Predictors of Response to Immune Checkpoint Inhibitors in Biliary Tract Cancer , 2021, Cancers.

[11]  Nan Yao,et al.  Intrahepatic cholangiocarcinoma induced M2-polarized tumor-associated macrophages facilitate tumor growth and invasiveness , 2020, Cancer cell international.

[12]  Y. Oda,et al.  Prognostic impact of tumor microvessels in intrahepatic cholangiocarcinoma: association with tumor-infiltrating lymphocytes , 2020, Modern Pathology.

[13]  Chen Wang,et al.  Targeting tumor-associated macrophages and granulocytic-myeloid-derived suppressor cells augments pd-1 blockade in cholangiocarcinoma. , 2020, The Journal of clinical investigation.

[14]  Y. Morine,et al.  Role of Central Hypo-enhancement in the Hepatic Arterial Phase of Dynamic Computed Tomography in Patients with Mass-Forming Intrahepatic Cholangiocarcinoma , 2020, World Journal of Surgery.

[15]  T. Pawlik,et al.  Number and Station of Lymph Node Metastasis After Curative-intent Resection of Intrahepatic Cholangiocarcinoma Impact Prognosis , 2020, Annals of surgery.

[16]  Y. Liao,et al.  Tumor Microenvironment Characterization in Gastric Cancer Identifies Prognostic and Immunotherapeutically Relevant Gene Signatures , 2019, Cancer Immunology Research.

[17]  G. Torzilli,et al.  Tumor-Infiltrating Lymphocytes and Macrophages in Intrahepatic Cholangiocellular Carcinoma. Impact on Prognosis after Complete Surgery , 2019, Journal of Gastrointestinal Surgery.

[18]  S. Antwi,et al.  Racial, Ethnic, and Age Disparities in Incidence and Survival of Intrahepatic Cholangiocarcinoma in the United States; 1995-2014. , 2018, Annals of hepatology.

[19]  H. Honda,et al.  Mass-forming intrahepatic cholangiocarcinoma: Enhancement patterns in the arterial phase of dynamic hepatic CT - Correlation with clinicopathological findings , 2017, European Radiology.

[20]  Y. Nakanuma,et al.  The favorable prognosis after operative resection of hypervascular intrahepatic cholangiocarcinoma: A clinicopathologic and immunohistochemical study. , 2016, Surgery.

[21]  M. Gonen,et al.  Recurrence Patterns and Disease-Free Survival after Resection of Intrahepatic Cholangiocarcinoma: Preoperative and Postoperative Prognostic Models. , 2016, Journal of the American College of Surgeons.

[22]  C. L. Tang,et al.  Factors Affecting the Enhancement Patterns of Intrahepatic Cholangiocarcinoma (ICC) on Contrast-Enhanced Ultrasound (CEUS) and their Pathological Correlations in Patients with a Single Lesion , 2015, Ultraschall in der Medizin - European Journal of Ultrasound.

[23]  Hao Li,et al.  Hepatitis C virus infection and the risk of intrahepatic cholangiocarcinoma and extrahepatic cholangiocarcinoma: evidence from a systematic review and meta-analysis of 16 case-control studies , 2015, World Journal of Surgical Oncology.

[24]  Y. Oda,et al.  Pathogenesis and classification of intrahepatic cholangiocarcinoma: different characters of perihilar large duct type versus peripheral small duct type , 2015, Journal of hepato-biliary-pancreatic sciences.

[25]  A. Shinagare,et al.  Correlation of CT patterns of primary intrahepatic cholangiocarcinoma at the time of presentation with the metastatic spread and clinical outcomes: retrospective study of 92 patients , 2014, Abdominal Imaging.

[26]  T. Nagayasu,et al.  Intrahepatic cholangiocarcinoma: relationship between tumor imaging enhancement by measuring attenuation and clinicopathologic characteristics , 2013, Abdominal Imaging.

[27]  M. Choti,et al.  Recurrence after operative management of intrahepatic cholangiocarcinoma. , 2013, Surgery.

[28]  J. Xu,et al.  Intrahepatic cholangiocarcinomas in cirrhosis are hypervascular in comparison with those in normal livers , 2012, Liver international : official journal of the International Association for the Study of the Liver.

[29]  B. Li,et al.  Hepatitis viruses infection and risk of intrahepatic cholangiocarcinoma: evidence from a meta-analysis , 2012, BMC Cancer.

[30]  R. Brunelli,et al.  Biliary tree stem/progenitor cells in glands of extrahepatic and intraheptic bile ducts: an anatomical in situ study yielding evidence of maturational lineages , 2012, Journal of anatomy.

[31]  Masakazu Yamamoto,et al.  Mass‐forming intrahepatic cholangiocarcinoma with marked enhancement on arterial‐phase computed tomography reflects favorable surgical outcomes , 2011, Journal of surgical oncology.

[32]  Jing Xu,et al.  Pathological classification of intrahepatic cholangiocarcinoma based on a new concept. , 2010, World journal of hepatology.

[33]  P. Gimotty,et al.  Hypoxia-inducible factor 2alpha regulates macrophage function in mouse models of acute and tumor inflammation. , 2010, The Journal of clinical investigation.

[34]  M. Makuuchi,et al.  Scenario 1 : Complication After a Surgical Procedure Not Caused by a Surgeon , 2022 .

[35]  H. Ojima,et al.  Therapeutic value of lymph node dissection during hepatectomy in patients with intrahepatic cholangiocellular carcinoma with negative lymph node involvement. , 2009, Surgery.

[36]  Y. Maehara,et al.  Decreased intratumoral arteries reflect portal tract destruction and aggressive characteristics in intrahepatic cholangiocarcinoma , 2009, Histopathology.

[37]  H-X Xu,et al.  Enhancement patterns of intrahepatic cholangiocarcinoma: comparison between contrast-enhanced ultrasound and contrast-enhanced CT. , 2008, The British journal of radiology.

[38]  P. Allavena,et al.  Macrophage polarization in tumour progression. , 2008, Seminars in cancer biology.

[39]  Jae Young Lee,et al.  Peripheral mass-forming cholangiocarcinoma in cirrhotic liver. , 2007, AJR. American journal of roentgenology.

[40]  Yoshihiko Maehara,et al.  Proposal of Progression Model for Intrahepatic Cholangiocarcinoma: Clinicopathologic Differences Between Hilar Type and Peripheral Type , 2007, The American journal of surgical pathology.

[41]  Z. Trajanoski,et al.  Effector memory T cells, early metastasis, and survival in colorectal cancer. , 2005, The New England journal of medicine.

[42]  M. F. Chen,et al.  Peripheral cholangiocarcinoma (cholangiocellular carcinoma): Clinical features, diagnosis and treatment , 1999, Journal of gastroenterology and hepatology.

[43]  C. Charnsangavej,et al.  Hepatocellular carcinoma and intrahepatic peripheral cholangiocarcinoma: enhancement patterns with quadruple phase helical CT--a comparative study. , 1999, Radiology.

[44]  M. Nagino,et al.  Macroscopic classification and preoperative diagnosis of intrahepatic cholangiocarcinoma in Japan. , 1999, Journal of hepato-biliary-pancreatic surgery.

[45]  M. Gassmann,et al.  Cellular and developmental control of O2 homeostasis by hypoxia-inducible factor 1 alpha. , 1998, Genes & development.

[46]  B. Choi,et al.  Peripheral cholangiocarcinoma of the liver: two-phase spiral CT findings. , 1997, Radiology.

[47]  Silvia Affò,et al.  Cancer-associated fibroblasts in intrahepatic cholangiocarcinoma progression and therapeutic resistance. , 2022, Advances in cancer research.

[48]  A. Jemal,et al.  Cancer statistics, 2014 , 2014, CA: a cancer journal for clinicians.